Effects of inhibition of the polyol pathway during chronic peritoneal exposure to a dialysis solution

Peritoneal Dialysis International

Volumn 25, Issue SUPPL. 3, 2005, Pages

  van Westrhenen, Roos ^a   Aten, Jan ^b   Aberra, Medhanit ^a   Dragt, Cindy A M ^a   Deira, Gregory ^a   Krediet, Raymond T ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiogenesis; Fibrosis; Polyol pathway; Zopolrestat

Indexed keywords

ALDEHYDE REDUCTASE; CD31 ANTIGEN; GLUCOSE; LACTIC ACID; PERITONEAL DIALYSIS FLUID; POLYOL; ZOPOLRESTAT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DIALYSATE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; FIBROSIS; HISTOPATHOLOGY; INHIBITION KINETICS; LONG TERM EXPOSURE; MALE; MESOTHELIUM; NONHUMAN; OMENTUM; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PUNCTURE; RAT; STATISTICAL SIGNIFICANCE;

EID: 21244478253     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502503s05     Document Type: Article

References (14)

1. Smit W, van den Berg N, Schouten N, Aikens E, Struijk DG, Krediet RT. Free-water transport in fast transport status: a comparison between CAPD peritonitis and long-term PD. Kidney Int 2004; 65:298-303.
2. Kapor-Drezgic J, Zhou X, Babzono T, Dlugosz JA, Hohman T, Whiteside C. Effect of high glucose on mesangial cell protein kinase C-delta and epsilon is polyol pathway dependent. J Am Soc Nephrol 1999; 10:1193-203.
3. Beyer-Mears A, Cruz E. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. Diabetes 1985; 34: 15-21.
4. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997; 40: 271-81.
5. Mizuno K, Kato N, Makino M, Suzuki T, Shindo M. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy. J Diabetes Complications 1999; 13:141-50.
6. Westrhenen van R, de Waart DG, Akman S, Krediet RT. Assessment of peritoneal fibrosis by conventional light microscopy and hydroxyproline measurements. Perit Dial Int 2004; 24:290-2.
7. Cheng HM, Gonzalez RG. The effect of high glucose and oxidative stress and lens metabolism, aldose reductase, and senile cataractogenesis. Metabolism 1986; 35(Suppl 1):10-14.
8. Wong TYH, Phillips AO, Witowski J, Topley N. Glucose-mediated induction of TGF-β1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int 2003; 63:1404-16.
9. Chung SSM, Ho ECM, Lam KSL, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003; 14(8 Suppl 3):S233-6.
10. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42:801-13.
11. Cameron NE, Cotter MA. Metabolic factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46(Suppl 2):S31-7.
12. Philips AO, Morrisey K, Steadman R, Williams JD. Decreased degradation of collagen and fibronectin following exposure of proximal cells to glucose. Exp Nephrol 1999; 7:449-62.
13. Tsukushi S, KatsuzakiT, Aoyama I, Takayama F, Miyazaki T, Shimokata K, et al. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. Kidney Int 1999; 55:1970-6.
14. Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chuyn DA, et al. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care 2004; 27:448-54.